BBOT
BridgeBio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BBOT
Bridgebio Oncology Therapeutics, Inc.
A clinical-stage biopharmaceutical company headquartered in South San Francisco,California,USA
Biological Technology
06/15/2021
02/09/2024
NASDAQ Stock Exchange
3
12-31
--
Common stock
256 E. Grand Avenue
Suite 104
South San Francisco
CA 94080
--
BridgeBio Oncology Therapeutics, Inc., was incorporated as a Cayman Islands exempted company on June 15, 2021. Effective August 12, 2025, the Company completed the previously announced Business Combination, with the combined company's place of incorporation in Delaware. BBOT is a clinical-stage biotechnology company whose mission is to transform the lives of cancer patients driven by the two most commonly mutated oncogenes, RAS and PI3Kα.
Company Financials
EPS
BBOT has released its 2025 Q3 earnings. EPS was reported at -1.03, versus the expected -0.34, missing expectations. The chart below visualizes how BBOT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
